Publications by authors named "Selami Bayram"

Claim this Profile
P
Predictive value of tumor marker index for pathological complete response following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Selami Bayram, Mustafa Serkan Alemdar, Ali Murat Tatli, Mustafa Ozdogan

World J Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.
Salih Tunbekici, Gokhan Sahin, Sercan Ön, Ahmet Oruc, Melek Karakurt Eryılmaz, Selami Bayram

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Pathologic Complete Response and Its Prognostic Value in Early Breast Cancer: A Real-World Cohort Study.
Selami Bayram, Ali Murat Tatli, Muharrem Okan Cakir, Mustafa Ozdogan

Curr Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Elif Şenocak Taşçı, Yasin Kutlu, Ömer Fatih Ölmez, Arda Ulaş Mutlu, Yasemin Gündoğdu, Selami Bayram

Expert Opin Pharmacother· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Yusuf Ilhan, Ali Murat Tatli, Fatih Teker, Arif Hakan Onder, Fatih Kose, Selami Bayram

Int J Gynecol Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy.
Hakan Bozcuk, Hasan Şenol Coşkun, Yusuf İlhan, Sema Sezgin Göksu, Mustafa Yıldız, Selami Bayram

Support Care Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, Mehmet Artaç, Nail Özhan, Selami Bayram

Eur Urol Focus· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, Nail Özhan, Burcu Çakar, Selami Bayram

Int J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Derya Kıvrak Salim, Selami Bayram, İsmail Gömceli, Ayhan Hilmi Çekin, Mustafa Karaca

Turk J Gastroenterol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis